drugset / Trial / NCT06271681
Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
Phase 4
Not yet recruiting
45 enrolled
VA Sierra Nevada Health Care System
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster with of 21-valent pneumococcal conjugate vaccine . Immune response will be assessed by opsonophagocytic assay reactivity.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2027-01-01
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PCV21 | Vaccine | — | — |